PTAB Considers Discretionary Denial Based on Parallel ITC Investigation, After Withdrawal of Fintiv Memo

May 9, 2025

Reading Time : 2 min

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

The patent at issue was directed to a photosensitive device capable of detecting visible and infrared electromagnetic radiation. Petitioner filed a petition for IPR challenging the patentability of several claims. Prior to the IPR, patent owner had asserted the patent against petitioner at the ITC and in district court. The ITC investigation was ongoing, but, as is customary, the district court case was stayed pending the conclusion of the ITC investigation. Patent owner argued in the IPR that the board should deny the petition under Fintiv because institution would incur significant inefficiencies and risk inconsistent outcomes. The board analyzed each of the six Fintiv factors in turn.

The board determined that factors two, three, and five weighed in favor of discretionary denial.  In reaching that finding, the board noted that the ITC investigation had a target completion date more than three months before the statutory deadline for a final written decision in the IPR, the ITC had already completed substantial work, and the parties were the same in the IPR and the ITC investigation. Factor one—whether there is a stay in the parallel proceedings—was neutral. Although there was a stay in the district court, there was no stay for the ITC investigation. The board noted that the lack of a stay for the ITC investigation elevated the importance of factor four, which concerns overlap between issues raised in the petition and parallel proceedings.

Regarding factor four, patent owner initially argued that the validity issues presented were nearly identical at the PTAB and in the ITC. Petitioner responded by withdrawing a ground from the IPR petition that overlapped with the ITC investigation and stipulating that “if the [b]oard institutes this IPR on the two remaining applicable grounds, petitioner will not assert invalidity in parallel litigation using as primary or combination references any of the references asserted in those grounds.” The board thereafter determined that the record no longer supported that the ITC would adjudicate the invalidity grounds raised in the petition and therefore factor four weighed against discretionary denial. The board also determined that “other considerations” under factor six weighed against denial, including that the petition’s merits were strong and that the narrowing of the petition minimized the burden on the parties and the board. 

In considering the factors as a whole, the board ultimately concluded that the strength of the merits and lack of overlap in proceedings outweighed any potential inefficiencies and declined to exercise its discretion in this situation.

Practice Tip:

In light of the withdrawal of the June 21, 2022 Fintiv Memo, patent owners faced with an IPR should now consider arguing for discretionary denial under Fintiv where there is a parallel ITC investigation.  Conversely, petitioners seeking to avoid discretionary denial should consider taking steps to minimize overlap between unpatentability grounds in a petition and invalidity positions taken in parallel proceedings.


Samsung Elecs. Co., Ltd. v. Sionyx, LLC, IPR2024-01431, Paper 21 (P.T.A.B. Apr. 10, 2025)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.